{
    "organizations": [],
    "uuid": "d073518f14cc3178339be85d6dd0b6e22d4f49d1",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-antisense-therapeutics-says-approv/brief-antisense-therapeutics-says-approval-received-for-phase-ii-trial-of-atl1102-in-duchenne-muscular-dystrophy-idUSFWN1QH1DP",
    "ord_in_thread": 0,
    "title": "BRIEF-Antisense Therapeutics Says ‍Approval Received For Phase Ii Trial Of Atl1102 In Duchenne Muscular Dystrophy​",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 28 (Reuters) - Antisense Therapeutics Ltd:\n* ‍APPROVAL RECEIVED FOR PHASE II TRIAL OF ATL1102 IN DUCHENNE MUSCULAR DYSTROPHY​ Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-28T08:20:00.000+02:00",
    "crawled": "2018-02-28T13:15:07.000+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "antisense",
        "therapeutic",
        "ltd",
        "received",
        "phase",
        "ii",
        "trial",
        "atl1102",
        "duchenne",
        "muscular",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}